Recent and Upcoming Drug Therapies for Pediatric Heart Failure
Pediatric heart failure (HF) is an important clinical condition with high morbidity, mortality, and costs. Due to the heterogeneity in clinical presentation and etiologies, the development of therapeutic strategies is more challenging in children than adults. Most guidelines recommending drug therap...
Enregistré dans:
Auteurs principaux: | Karla L. Loss, Robert E. Shaddy, Paul F. Kantor |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Frontiers Media S.A.
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/53b1d27df00c43e6acbd03d5d6a1d915 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy
par: Amy Hyein Kim, et autres
Publié: (2022) -
Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
par: Domingo Pascual-Figal, et autres
Publié: (2021) -
Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
par: M. O.E. Irhuma, et autres
Publié: (2016) -
Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries
par: Marat Fudim, et autres
Publié: (2021) -
A study of association between heart failure with preserved ejection fraction with hypertension and diabetes mellitus
par: Swapan Sarkar, et autres
Publié: (2021)